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Background: The osteoarthritis (OA) treatment in humans and in animals is a major orthopaedic challenge because
there is not an ideal drug for preserving the joint structure and function. The aim of this study was to assess the
effects of the treatment with oral glucosamine and risedronate alone or in combination on articular cartilage,
synovial membrane and subchondral bone in an experimental rabbit model of OA. Osteoarthritis was surgically
induced on one knee of 32 New Zealand White rabbits using the contralateral as healthy controls. Three weeks
later treatments were started and lasted 8 weeks. Animal were divided in four groups of oral treatment: the first
group received only saline, the second 21.5 mg/kg/day of glucosamine sulfate, the third 0.07 mg/kg/day of
risedronate; and the fourth group both drugs simultaneously at the same dosages. Following sacrifice femurs were
removed and osteochondral cylinders and synovial membrane were obtained for its histological and micro-CT
evaluation.
Results: Sample analysis revealed that the model induced osteoarthritic changes in operated knees. OA placebo
group showed a significant increase in cartilage thickness respect to the control and inflammatory changes in
synovial membrane; whereas subchondral bone structure and volumetric bone mineral density remained
unchanged. All the treated animals showed an improvement of the cartilage swelling independent of the drug
used. Treatment with glucosamine alone seemed to have no effect in the progression of cartilage pathology while
risedronate treatment had better results in superficial fibrillation and in resolving the inflammatory changes of the
tissues, as well as modifying the orientation of trabecular lattice. The combination of both compounds seemed to
have additive effects showing better results than those treated with only one drug.
Conclusions: The results of this animal study suggested that glucosamine sulfate and risedronate treatment alone
or in combination may be able to stop cartilage swelling. The risedronate treatment could partially stop the
fibrillation and the inflammation of synovial membrane as well as modify the orientation of trabeculae in healthy
and in osteoarthritic knees.
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Among the wide range of pharmacological treatments
for osteoarthritis (OA), the disease-modifying drugs, also
called SYSADOA (Symptomatic Slow Action Drugs for
Osteoarthritis), have been shown to relieve the symptoms
and progression of OA. The beginning of their action
is slow, usually from the sixth week, and their effect
continues over a period of time after stopping treatment.
Included in this group of drugs, glucosamine has demon-
strated its efficacy and clinical relevance in several clinical
trials [1-3] and animal models [4,5] helping to restore the
proteoglycan matrix of the articular cartilage, to protect
damaged cartilage from metabolic impairment [6] and
having a mild anti-inflammatory activity [4]. Glucosamine
is an endogenous aminomonosaccharide synthesized by
chondrocytes from glucose and basic precursor of the
structure of glycosaminoglycans and proteoglycans, which
form part of the non-cellular connective tissue. This
component is primarily responsible for the mechanical
function of cartilage. There are several molecular presen-
tations for glucosamine preparations, although the results
are more favourable for glucosamine sulfate than for glu-
cosamine hydrochloride [7].
Bisphosphonates (BPs), non-hydrolysable analogues of
inorganic pyrophosphate, have been approved for the
treatment of pathologies with an increased bone turn-
over (like osteoporosis or Paget's disease). They inhibit
bone resorption by causing the osteoclast to internalize
the bisphosphonate and inducing its apoptosis. There
are many clinical and experimental evidences of other
biological effects of BPs, which may act on other cells of
the joint, such as macrophages or chondrocytes. The
bisphosphonates seems to have a chondroprotective ef-
fect [8,9], to inhibit matrix metalloproteinases [10-12] or
even to inhibit cytokines [13,14] and have been reported
to exert chondroprotective and analgesic action in OA
[15] even though the exact mechanisms remained un-
clear. Risedronate or risedronic acid is one of the most
potent BPs and has demonstrated several beneficial ef-
fects on OA progression. It was reported that select
combinations of risedronate and non-steroidal antiin-
flammatory drug therapy in the early stages of OA pre-
serve trabecular bone mass and reduce the impact of
osteophyte bony adaptations and bone marrow lesion-
like stimulus in a rat model [16]. Risedronate has also
shown a reduction of bone mineral loss at sites where
the medial cruciate ligament attaches to bone [17] and a
conservation effect on periarticular bone and ligament
mechanical properties [18] in rabbit models. Studies in
guinea pig models suggest smaller cartilage lesions in
risedronate-treated joints versus control groups [19].
The efficacy of risedronate in the treatment of human
OA was investigated on some clinical trials. BRISK
(British Study of Risedronate in Structure and Symptomsof Knee OA) study [20] revealed clear trends towards
improvement in both joint structure and symptoms in
patients with primary knee OA treated with risedronate,
but KOSTAR (Knee OA Structural Arthritis) study [21]
shown that risedronate (compared with placebo) did not
improve signs or symptoms of OA, nor did it alter its
progression, although a reduction in the level of cartilage
degradation biochemical markers was observed.
Glucosamine sulfate and sodium risedronate, adminis-
tered individually or in combination, act directly on the
joint structures affected by osteoarthritis (OA). The aim
of this study was to determine the magnitude of changes
that occur in the knee joint in the early stages of osteo-
arthritis and evaluate the effects of the glucosamine or
risedronate administration on the joint structure in a
rabbit model of OA. Furthermore, it was desired to con-
firm whether the administration of glucosamine in com-
bination with an antiresorptive therapy like risedronate




Thirty-two healthy adult female New Zealand White rab-
bits (Granja San Bernardo, Navarra, Spain) of 6–7 months
of age and mean weight 5 Kg were used in this study after
approval of the protocol by the Ethical Committee of the
University of Santiago de Compostela (Spain). The rabbits
housing, daily monitoring and experimental procedures
were conducted in the Animal Experimentation Service
Facility of the Santiago de Compostela University (Lugo,
Spain) by accredited veterinarians trained in laboratory
animal science. All animal handling and experimentation
was performed in accordance with Spanish and European
Union regulations about care and use of research animals
and this paper has been written following the ARRIVE
guidelines [22].
After three weeks of quarantine OA was induced by an-
terior cruciate ligament transection (ACLT) and partial
medial meniscectomy on one knee randomly chosen using
the contralateral joint as healthy control. To perform the
surgical procedure, animals were firstly pre-medicated with
a combination of medetomidine (50 μg/Kg IM, Domtor,
Esteve, Barcelona, Spain) and ketamine (25 mg/Kg IM,
Imalgène 1000, Merial, Toulouse, France) and anesthetized
using isoflurane general anaesthesia (Inspiratory Fraction
ISO 2.5-4%, Isova-vet, Schering-Plough, Madrid, Spain). Each
animal received peri- and post-operative analgesia using
buprenorphine (1 mg/Kg IM, Buprex, RB Pharmaceuticals,
Berkshire, UK), antibiotic prophylaxis during one week with
enrofloxacin (15 mg/Kg SC once a day, Ganadexil 5%,
Invesa, Barcelona, Spain) and pain control with meloxicam
(20 μg/Kg SC, Metacam, Boehringer Ingelheim España,
Barcelona, Spain) during three days. During all the study
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activity and monitored once a day by trained staff to asses
changes in general health.
Treatments began 3 weeks after surgery. Drugs were
orally administered directly into the mouth diluted in
saline solution (NaCl) 0.9% during 8 weeks. The animals
were randomly divided into 4 experimental groups of 8
animals each: the first group received only vehicle, the
second 21.5 mg/kg/day of glucosamine sulfate, the third
0.07 mg/kg/day of risedronate, and the fourth group was
treated with both drugs simultaneously (at doses indi-
cated above). Operated joints formed OA groups and
contralateral joints healthy groups (Figure 1).
Necropsy and preparation of histological samples
Rabbits were sacrificed by a sodium pentobarbital over-
dose (100 mg/Kg IV, Dolethal, Vétoquinol especialidades
veterinarias SA, Madrid, Spain) after sedation with keta-
mine (25 mg/Kg IM, Imalgène 1000, Merial, Toulouse,
France). All complete knee joints were removed and
immersed in 10% buffered formalin.
After dissecting the articulation, three different samples
were obtained from each joint: a synovial membrane sec-
tion adjacent to the patellar ligament and two 2.9 mm
diameter and 8 mm length cores of bone and cartilage
from the medial femoral condyle, took at the same
anatomical locations in every specimen, using a bone tre-
phine. The first bone cylinder was decalcified (Osteodec,
Bio-Optica, Milano, Italy) and together with the articular
capsule, were paraffin embedded and sectioned using a
microtome (Leica RM 2255, Leica Biosystems Nusshoch
GmbH, Germany). Slides were stained with hematoxilin-
eosin (H-E) and in addition with safranin O-fast green in
the case of the bone and cartilage cylinder.
The second cylinder was initially used to assess the 3D
architecture of the cartilage and subchondral bone by
micro-computed tomography (micro-CT) and latter pro-
cessed for undecalcified ground sections in conformityFigure 1 Experimental design. Rabbits were divided into four groups, wh
groups, while contralateral joints were used as healthy controls. CTRL: cont
glucosamine sulphate and risedronate applied simultaneously.with the method described by Donath [23]. Summarily,
the specimens were dehydrated in ascending grades of
alcohol, infiltrated and embedded with a light curing resin
(Technovit 7200-VLC, Heraus Kulzer GmbH, Werheim,
Germany), sectioned and polished using a grinding ma-
chine (EXAKT Apparatebau, Norderstedt, Germany) up
to approximately 40 μm in thickness and stained using the
Lévai-Laczkó method [24].
All the sections were observed using light microscopy
and a PC-based image capture system (BX51, DP71,
Olympus Corporation, Japan) for histometrical analysis.
Microscopic evaluation
Undecalcified sections
Quantitative histology was performed using unde-
calcified sections applying morphometrical parameters
previously published [25], by a masked examiner and
using PC-based image analysis programs (Cell-sens 1,5
(Olympus Corporation, Japan) and Micro-image 4.0
(Media cybernetics, Bethesda, MD, USA). The parame-
ters evaluated were:
(A) Subchondral cortical bone thickness (SB.Th) and
cartilage thickness (Cg.Th). SB.Th is defined as the mean
distance between the cartilage and the subchondral
cortical bone limits. Cartilage thickness was divided in
non-calcified cartilage thickness (nCg.Th) and calcified
cartilage thickness (cCg.Th) using the tidemark as refe-
rence. All were calculated as mean distances (Figure 2A).
(B) Surface undulations of the cartilage (FI), defined as
the difference in between the length of the upper margin
of the cartilage and the width of the same measurement
area.
(C) Trabecular subchondral bone area (Tb.A) and tra-
becular separation (Tb.Sp) in subchondral bone. To ob-
tain these measurements, a region of interest (ROI) was
defined as a 4 × 2 mm area beginning immediately after
the subchondral cortical bone. Tb.A was defined as the
percentage of trabecular bone in this region and the Tb.ich receive different treatments. Operated joints constituted OA
rol (healthy); GS: glucosamine sulphate; RS: risedronate; GS&RS:
Figure 2 Microscopic evaluation. 2A (undecalcified sections): measurement of cartilage and subchondral bone cortical thickness (a: nCg.Th; b:
cCg.Th; c: SB.Th). 2B and 2C (decalcified sections): Assessment of chondrocyte clusters (black arrow in Figure 2B), grade of safranin stain in
samples (2B and 2C), alterations in cartilage surface (2C).
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the diagonal of the ROI (Tb.Sp = (1/Tb.N)-Tb.Th).
Decalcified sections
Synovial membrane and decalcified sections of bone core
biopsies, including cartilage, were used for evaluating
articular changes. The evaluation was always performed
by two independent observers following guidelines already
published [26,27]. The parameters evaluated were:
(A) Severity of cartilage pathology: Grade of alteration
of cartilage surface (Figure 2C).
(B) Severity of chondrocyte pathology: Number and
distribution of chondrocytes in cartilage
(Figure 2B).
(C) Severity of proteoglycan pathology: depth of the
“red” colour of the staining (Figure 2B and
Figure 2C).
(D) Tidemark integrity.
(E) Microscopic changes of synovial membrane:
evaluating the lining cells, presence of hyperplasia
and cellular inflammatory infiltration.
The gradation of the affectation of structures in these
decalcified samples was as follows: in cartilage, chondro-
cyte and proteoglycan pathology from 0 (normal) to 4
(completely affected) and in tidemark and synovial
membrane from 0 to 2.
Micro-computed tomography
Subchondral bone cores containing articular cartilage were
assessed with high-resolution X-ray micro-CT (SkyScan
1172, Bruker micro CT NV, Kontich, Belgium) in Tra-
beculae S.L. research lab (Ourense, Spain). The X-ray
source was set at 50 kV and 200 μA, with a pixel size of
12 μm and the use of a 0.5 mm aluminium filter. Images
were reconstructed based on Feldkamp algorithm [28],
and segmented into binary images using adaptive local
thresholding methods. Standard indices of cancellous bone
microstructure were determined [29], including bonevolumetric fraction (BV/TV), trabecular thickness (Tb.Th)
and separation (Tb.Sp), trabecular number (Tb.N), tra-
becular bone pattern factor (Tb.Pf), structural model index
(SMI), and degree of anisotropy (DA).
Volumetric bone mineral density (vBMD) was deter-
mined in the analysed region of subchondral bone by
calibration against hydroxyapatite phantoms of known
density. Two phantoms, 250 and 750 mg/cm3 of hydro-
xyapatite, were scanned under the same conditions than
bone samples. An estimation of vBMD of each of the
samples was obtained comparing the attenuation coeffi-
cients of the phantoms and bone.
An additional scan was made for each sample with in
order to correctly visualize the non-calcified part of the
articular cartilage and measuring its volume (nCg.V) and
mean thickness (nCg.Th) three-dimensionally. For this
scans, X-ray source was set at 60 kV and 167 μA, voxel
size was reduced until 5 μm, and no filter was used.
Statistical approach
Results were expressed as mean ± standard deviation. The
normality of the data was assessed using the Shapiro-Wilk
test. Levene's test was used to assess the equality of va-
riances of normal variables and the statistical comparison
was performed using ANOVA. Post-hoc analysis was
made by Tukey's HSD test or by Games-Howell test for
parameters with equal or different variances respectively.
For non-normal variables, statistical comparison was per-
formed using Kruskal-Wallis H test and post-hoc analysis
using Dunn’s test. All statistical analyses were performed
using commercially available software IBM SPSS Statistics
19 (IBM, Armonk, NY, USA). Differences were considered
significant when p < 0.05.
Results
During the procedure no changes in weight or general
condition were observed. All animals tolerated well the
treatments.
From a total of 64 joints, one had to be excluded due
to an infection (OA group); the rest 63 presented an
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fication of the original protocol was necessary.
Histology quantitative results
No parameters measured in cartilage (Figure 3) and in
subchondral bone (data not shown) showed significant
differences; although appears to be a little tendency to
thickening of the cartilage in the OA group respect to
controls standing the results of the three OA treatment
groups (OA +GS, OA + RS, OA + GS&RS) in between
OA and normal (Figure 4). Respect to surface undula-
tions (FI) there were no statistical differences between
groups but OA and OA +GS have more surface fibrilla-
tion than controls, OA + RS and OA +GS&RS.
Although the results discussed above were not statisti-
cally significant, in the microscopic images of the calci-
fied samples was possible to observe several differences
between groups (Figure 4). The thickness of the cartilage
in the OA group (4B) was greater than in the three treat-
ment groups (4C, 4D, 4E) being these groups more
similar to the control (4A). The distribution of the chon-
drocytes in the cartilage was different too, showing more
disorganization in the OA group (4B) than in the others.
Finally in the OA picture we could see the loss of the
part of the calcified cartilage as well as in the glucosa-
mine treated group (4C) and not in the others.
Histology qualitative results (Table 1)
In cartilage pathology there was statistical significance
between control groups and three of the treatment
groups (OA, OA +GS and OA + RS) but not with OA +
GS&RS. This group (OA +GS&RS) had not differences
with any control group but it presented differences withFigure 3 Comparison between the histological parameters of the cart
OA: osteoarthritis + placebo; CTRL + GS: healthy + glucosamine; OA + GS: oste
osteoarthritis + risedronate; CTRL + GS&RS: healthy + combined treatment of g
treatment of glucosamine and risedronate.the other OA groups. The severity of chondrocyte pa-
thology, the proteoglycan pathology and the tidemark in-
tegrity, showed no statistical changes between groups
(Figure 5); but, although the differences were not signifi-
cant, in the OA group there is a loss of the proteoglycan
content in all the cartilage (as show in Figure 5B) which is
less pronounced in the treatment groups, as well as a bet-
ter conservation of the normal distribution of the chon-
drocytes in rows in the treatment groups (5C, 5D, 5E).
The three variables measured in synovial membrane
(Figure 6) showed significant differences between CTRL
and OA placing the treatment groups in between them
with different results. In lining cell characteristics risedro-
nate treated osteoarthritic groups (OA + RS and OA +
GS&RS) had differences with OA group, but not glu-
cosamine osteoarthritic group (OA +GS). The OA+ RS
showed not differences with any control group and the
OA+GS&RS group had differences with all the groups
(healthy and OA) unless with OA + RS.
In hyperplasia the CTRL group had differences with
the four OA groups and the OA placebo group with all
the rest (controls and osteoarthritic), standing the results
of the three treatment groups in between OA and
healthy. The glucosamine OA group (OA +GS) had dif-
ferences between the two risedronate treated groups
(OA + RS and OA +GS&RS) but these two did not differ
between them.
With respect to the cell infiltration in synovial mem-
brane, the CTRL placebo group showed differences with
OA, OA +GS and OA + RS but not with OA +GS&RS
and this one showed differences with OA group and
with OA +GS standing closer to normality than the
other surgically induced groups.ilage obtained from undecalcified samples. CTRL: healthy + placebo;
oarthritis + glucosamine; CTRL + RS: healthy + risedronate; OA + RS:
lucosamine and risedronate; OA + GS&RS: osteoarthritis + combined
Figure 4 Representative histology images of Lévai-Laczkó stained undecalcified sections. Magnification 10x. A: CTRL; B: OA; C: OA + GS;
D: OA + RS; E: OA + GS&RS. Observe the reduction in cartilage thickness in the treatment groups (C, D, E) in regard to the OA group (B).
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Micro-CT data is shown on Figure 7. The results obtained
in the osteoarthritic group (OA) compared to the healthy
control group (CTRL) showed that there were no differ-
ences in any of the microstructural parameters referred to
subchondral bone, or in volumetric bone mineral density
(vBMD). However, non-calcified cartilage thickness (nCg.
Th) was significantly increased in the OA group (p < 0.05).Table 1 Comparison between experimental groups of the diff
synovial alterations, obtained from decalcified samples
CONTROL CTRL CT
Median (25, 75) Me
Microscopic grading of cartilage alterations
Severity of cartilage pathology 0 (0, 0.5)e,f,g 0 (
Severity of chondrocyte pathology 0 (0, 1) 0.5
Severity of proteoglycan pathology 0 (0, 0) 0.5
Tidemark integrity 1 (0.75, 2) 0.5
Microscopic grading of synovial changes
Lining cells characteristics 0 (0, 0)e,f,h 0 (
Presence of hyperplasia 0 (0, 0)e,f,g,h 0 (
Cell infiltration characteristics 0 (0, 0)e,f,g 0 (
OSTEOARTHRITIS OA OA
median (25, 75) me
Microscopic grading of cartilage alterations
Severity of cartilage pathology 1 (0.5, 1.5)a,b,c,d,h 1 (
Severity of chondrocyte pathology 1 (0.5, 1.75) 1 (
Severity of proteoglycan pathology 1 (0, 2) 1 (
Tidemark integrity 0 (0, 1.5) 0 (
Microscopic grading of synovial changes
Lining cells characteristics 1 (1, 1)a,b,c,d,g,h 1 (
Presence of hyperplasia 1 (1, 1.75)a,b,c,d,f,g,h 1.5
Cell infiltration characteristics 1 (0.25, 1)a,b,c,d,h 0.7
CTRL: healthy + placebo; OA: osteoarthritis + placebo; CTRL + GS: healthy + glucosam
OA + RS: osteoarthritis + risedronate; CTRL + GS&RS: healthy + combined treatment o
treatment of glucosamine and risedronate. Statistical differences p < 0.05: a vs. CTRL
g vs. OA + RS, h vs. OA + GSRS.In healthy samples treated with glucosamine (CTRL +
GS) has not been observed any change in the structural
properties of the subchondral bone compared to CTRL
group. The morphology of the cartilage did not differ
between both groups. Treatment with GS in osteoarth-
ritic joints (OA +GS) caused no significant changes in
subchondral bone versus untreated osteoarthritic group
(OA), however it reduced the thickness of cartilageerent scores for microscopic grading of cartilage and
RL + GS CTRL + RS CTRL + GS&RS
dian (25, 75) Median (25, 75) Median (25, 75)
0, 0)c,e,f,g 0 (0, 0.5)b,e,f,g 0 (0, 1)e,f,g
(0, 1.25) 0 (0, 1) 0.5 (0, 1)
(0, 1) 0 (0, 0) 0 (0, 0)
(0, 1) 1 (0, 1) 1 (1, 1)
0, 0)e,f,h 0 (0, 0)e,f,h 0 (0, 0)e,f,h
0, 1)e,f,h 0 (0, 0)e,f,g,h 0 (0, 0)e,f,g,h
0, 0)e,g 0 (0, 0)e,f 0 (0, 0)e,f
+ GS OA + RS OA + GS&RS
dian (25, 75) median (25, 75) median (25, 75)
1, 2)a,b,c,d,h 1 (0.5, 1.5)a,b,c,d,h 0 (0, 0.625)e,f,g
1, 3) 1 (0.5, 1.5) 1 (0, 1.125)
0.5, 3) 1 (0, 2.75) 3 (0.75, 4)
0, 0) 1 (1, 1) 1 (0.25, 1)
0, 2)a,b,c,d,g,h 0 (0, 0.25)e,f 0 (0, 0.625)a,b,c,d,e,f
(1, 2)a,b,c,d,e,g,h 0.5 (0, 1)a,c,d,e,f 1 (0, 1)a,b,c,d,e,f
5 (0, 1)a,b,c,d,g,h 0 (0, 0.25)a,f 0 (0, 0.25)e,f
ine; OA + GS: osteoarthritis + glucosamine; CTRL + RS: healthy + risedronate;
f glucosamine and risedronate; OA + GS&RS: osteoarthritis + combined
, b vs. CTRL + GS, c vs. CTRL + RS, d vs. CTRL + GSRS, e vs. OA, f vs. OA + GS,
Figure 5 Representative histology images of safranin O stained sections. Magnification 20x. A: CTRL; B: OA; C: OA + GS; D: OA + RS; E: OA +
GS&RS. Observ the better conservation of the normal characteristics of the cartilage in the two risedronate treated groups (D, E) respect to OA
(B) and GS (C).
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values between CTRL and OA groups, i.e. showing sig-
nificant differences versus CTRL group too (p < 0.05).
Healthy group treated with risedronate (CTRL + RS)
compared with the CTRL group, presented a reduction
of the degree of anisotropy (p = 0.000). Both BV/TV and
vBMD were increased in the treated group, but the dif-
ferences compared to CTRL group did not become sig-
nificant. Cartilage structure was neither altered in the
CTRL + RS group. By the other hand, in OA samples,
risedronate appeared to have similar effects on the sub-
chondral bone. The only parameter which revealed sig-
nificant differences between OA and OA + RS groups
was the degree of anisotropy (p = 0.001). These data sug-
gested that treatment with risedronate alter trabeculae
orientation, becoming trabecular lattice more disorga-
nized than in untreated groups, diminishing trabecular
separation and increasing trabecular number. But sur-
prisingly, we have observed changes in the morphology
of the cartilage. nCg.Th in OA + RS group was smaller
than that of OA group (p < 0.05), although showing dif-
ferences also versus CTRL group (p < 0.05).
In the healthy group treated with the combination of
both drugs (CTRL +GS&RS) the only change in subchon-
dral bone was on DA (p = 0.000 versus CTRL), probably
due to the effect of risedronate described above. BV/TV
and vBMD were again increased in the treated group ver-
sus CTRL group but they did not show significant dif-
ferences. The combination of both drugs did not alter theFigure 6 Representative histology images of synovial membrane sect
GS&RS. In the risedronate treated groups (D and E) the characteristics are mo
infiltrations of inflammatory cells as in OA (B).structure of the cartilage. In OA samples, the effect of
combined therapy on bone was again a decrease in DA
(p = 0.000 versus OA). In relation to the cartilage, com-
bined therapy was also able to stop swelling in OA +
GS&RS group, reducing nCg.Th value, which showed sig-
nificant differences versus OA and CTRL groups (p < 0.05
in both cases).
Discussion
Different animal models have been widely used for the
study of the efficacy of therapies to improve, resolve or
prevent the OA. The surgically induced models (joint in-
stability) produce a gradual progression of the degenera-
tive changes in the joint that mimic the pathogenesis and
pathology of the human traumatic OA [30,31]. The rabbit
model was extensively used for testing potential chondro-
protective agents including bisphosphonates [18,32] and
glucosamine [4,33]. Previously published data showed that
most rabbits with anterior cruciate ligament transection
develop cartilage degeneration [33,34] and subchondral
bone alterations [33] as soon as 8 weeks postsurgery. In
the present study, the development of OA was not still
advanced at eleven weeks postsurgery, although it was
enough to produce detectable changes in the articular car-
tilage but not in the subchondral bone. Articular cartilage
appears in a state of swelling -characteristic of the early
stages of the disease- previous to its erosion and des-
truction [35]. The subchondral bone, however, had not
the typical sclerosis associated with this pathology, notions. Magnification 20x. A: CTRL; B: OA; C: OA + GS; D: OA + RS; E: OA +
re similar to control (A), in glucosamine treated (C) were present
Figure 7 Comparison between the micro-CT parameters. CTRL: healthy + placebo; OA: osteoarthritis + placebo; CTRL + GS: healthy + glucosamine;
OA + GS: osteoarthritis + glucosamine; CTRL + RS: healthy + risedronate; OA + RS: osteoarthritis + risedronate; CTRL + GS&RS: healthy + combined
treatment of glucosamine and risedronate; OA + GS&RS: osteoarthritis + combined treatment of glucosamine and risedronate.
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group and the untreated OA group in any of the micro-
structural parameters analysed by either histology or
micro-CT.
In animal models of OA histological assessment of ar-
ticular cartilage, using mainly Mankin [36] or modified
Mankin scoring systems in decalcified samples, was con-
sidered the gold standard for the evaluation of the pre-
sence, extent and severity of the pathology [25]. However,
because this is a subjective scoring system with the of
inter- and/or intra-observer variability, the histomorpho-
metry of calcified samples, using computer analysis sys-
tems, was introduced with a greater degree of objectivity
and reproducibility [25]. Micro-CT had become in the last
years the gold standard for the three-dimensional analysis
of bone microstructure but with soft tissues as the
articular cartilage the technique presents problems due to
its low x-ray transmission. Normally to quantify the struc-
ture of cartilage using micro-CT, was necessary the use of
complex staining methods with radiopaque contrast
agents [37-39]. For the present study we used quantitative
(histomorphometry) and qualitative microscopic evalua-
tions and also micro-CT scanning, to analyse the structure
of subchondral bone and articular cartilage in calcified
and non-calcified samples in all the groups of treatment.
For the evaluation with micro-CT we had adjusted the
scan conditions for a visualization of articular cartilage
enough to be able to quantify its morphology without theuse of contrast techniques. Mineralized tissue was usually
scanned at 50 KV and 200 μA of the X-ray source, and
with the use of aluminium filters. After a series of trials to
get the visualization of cartilage, we decided to increase
the voltage to 60 KV, decrease the intensity to 167 μA,
and remove the aluminium filter. In this way we have
scanned the articular cartilage obtaining valid images for a
proper binarization and to quantify its thickness and vo-
lume. Due to different scanning conditions required to
visualize subchondral bone and cartilage, each sample was
scanned twice (once for each of the conditions mentioned
above). This is the first time, to the best knowledge of the
authors, that the morphology of articular cartilage is quan-
tified by micro-CT without the use of contrast agents.
The efficacy of the glucosamine treatment for OA was
tested in several in vitro and in vivo models as well as in
clinical trials. In vitro, Bassler et al. [40] showed a stimula-
tory effect of glucosamine on the biosynthetic activity on
human chondrocytes probably due to the inhibition of the
degradation of proteoglycans and the stimulation of its
synthesis [41,42]. This biosynthetic activity seen in vitro
was not always corresponded with the findings in animal
models and in clinical trials in which some supported the
hypothesis that glucosamine is a symptom-modifying
agent for OA [43,44] while others had detected no effect
[45,46]. In our study the glucosamine sulfate treatment
alone seemed not alter the structure of subchondral bone
measured by histomorphometry and by micro-CT nor in
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fate treatment did not seem to have any structural effect
on cartilage healthy samples, in OA was able to partially
stop the swelling of articular cartilage reaching intermedi-
ate values of cartilage thickness (Cg.Th) between CTRL
and OA groups (measured in calcified samples) although
the results are not statistically significant. Using histomor-
phometry we could observe that in OA+GS samples the
surface undulations (FI) were more elevated than in other
treatment groups, but still lower than the OA group; this
findings were in conformity with those of other groups
who reported that the administration of glucosamine did
not prevent fibrillation and/or erosions of the articular
cartilage in an ACLT model in rabbits although there was
an overall trend toward a reduction in the severity of the
disease [2,5]. With respect to the severity of changes in
synovial membrane, which represents the anti-
inflammatory effect of the drug, we could see that the
values of the OA+GS group were similar to the OA
group (both had statistical differences with the control
groups) so in our case, the drug did not show the expected
anti-inflammatory action in the synovial membrane (This
results differ from those of Pavelka et al. [2] where they
observed improvement of synovitis).
Early in the pathogenesis of OA a period of periarticu-
lar osteopenia was developed prior to the latter stage of
subchondral bone sclerosis [47]; this osteopenia had also
been reported after anterior cruciate ligament injury in
clinical trials [48] and a significant reduction in the bone
mineral density was reported in patients with mild OA
when it was compared with healthy ones [49]. With the
purpose of inhibiting bone remodelling and consequent
osteopenia, bisphosphonates were proposed as a possible
treatment for OA in the early stages of the disease be-
cause they may help in preserving periarticular bone
mechanical properties [50]. Risedronate, a potent amino-
bisphosphonate, was shown its effectiveness in con-
serving periarticular bone properties in animal models
of OA [50]. In the present study in rabbits, risedronate
administered alone or in combination with glucosamine
seemed to considerably modify the orientation of
trabecular lattice both in healthy and OA subchondral
bone, measured by micro-CT (groups CTRL + RS, CTRL +
GS&RS, OA + RS and OA+GS&RS), represented as a
diminution in Tb.Sp and an increase in Tb.N showing a
trend to bone formation in animals treated with risedro-
nate, as was previously published by other authors [50,51].
When the cartilage was assessed, in calcified samples mea-
sured by micro-CT and quantitative histomorphometry,
risedronate was able, at least in part, to reduce the cartil-
age swelling perhaps due to an anti-inflammatory activity
[14] reaching intermediate values between control and
OA, and, as seen in histomorphometry the values of
superficial fibrillation were similar to those in the controlsand lower than in the OA ones. In the safranin-O/fast
green stained samples, the results for the groups treated
with risedronate were in between OA and controls sug-
gesting an improvement of the cartilage pathology. Similar
results as those obtained in the present study were re-
ported previously; Myers et al. [52] established that the
nitrogen-containing bisphosphonates reduced early turn-
over of cancellous and subchondral bone in the canine
anterior cruciate ligament transection model but in this
model mild OA changes in cartilage were detectable
12 weeks post-surgery. In the present study we found a
favourable effect of risedronate treatment (alone and in
combination with glucosamine) on the inflammatory
changes in the synovial membrane. The anti-inflammatory
and pain relieving efficacy of bisphosphonates was re-
ported before [53] but these studies revealed an anti-
inflammatory activity not related to ameliorating the syno-
vitis [54].
Conclusions
Oral risedronate and glucosamine sulfate, alone or in
combination, were able to improve cartilage swelling in
the early stages of OA in a rabbit instability model. Oral
risedronate but not glucosamine could preserve cartilage
from superficial fibrillation and improve the inflamma-
tory changes in synovial membrane. On subchondral
bone, risedronate could modify the orientation of tra-
becular lattice in all treatment groups (healthy and OA)
indicating its effect in bone although it has been admi-
nistered orally to the rabbits.
The study also demonstrated the validity of the animal
model, and that micro-CT could be a valid technique to
detect morphological changes in articular cartilage with
comparable results to those of histomorphometry.
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